News
CYYNF
0.150
NaN%
--
Bioscience Fund Exits Substantial Holding in Cynata Therapeutics
TipRanks · 06/23 05:58
Cynata to Host Investor Webinar on Results Update
TipRanks · 06/21 23:07
Cynata’s CYP-004 Fails to Outperform Placebo in Phase 3 Knee Osteoarthritis Trial
TipRanks · 06/19 00:18
Cynata Halts CYP-001 GvHD Trial After Phase 2 Misses Efficacy Goals
TipRanks · 06/17 02:12
Cynata Seeks ASX Trading Suspension Ahead of Key Clinical Trial Results
TipRanks · 06/16 11:10
Cynata Sets June–July Timeline for Pivotal Stem Cell Trial Readouts
TipRanks · 05/26 23:15
Cynata Plans Placement of Up to 6 Million New Shares
TipRanks · 05/03 23:26
Cynata Nears Key Trial Readouts as Cell Therapy Sector Gains Traction
TipRanks · 04/30 01:46
Cynata Seeks Trading Halt Ahead of Share Placement Capital Raising
TipRanks · 04/30 00:31
Cynata Options Expire Unexercised, Streamlining Capital Structure
TipRanks · 04/06 23:32
Cynata Reaches Key Phase 2 Milestone in aGvHD as Late-Stage Cell Therapy Pipeline Advances
TipRanks · 03/29 22:20
Cynata Narrows Half-Year Loss but Faces Going Concern Uncertainty
TipRanks · 02/26 04:58
Cynata to Host Investor Webinar and Expand Online Engagement With Shareholders
TipRanks · 02/03 22:55
Cynata Nears Key Data Readouts as Pivotal Cell Therapy Trials Advance
TipRanks · 01/29 00:48
Cynata Raises $1.2m via At-The-Market Facility to Support Cell Therapy Pipeline
TipRanks · 01/23 06:58
Cynata Completes Enrollment in Phase 2 aGvHD Trial
TipRanks · 12/14/2025 23:37
Cynata’s CYP-001 Therapy Shows Promise in Kidney Transplant Trial
TipRanks · 12/03/2025 22:58
Cynata Therapeutics Updates Director’s Securities Holdings
TipRanks · 11/30/2025 23:37
Cynata Therapeutics Announces Change in Director’s Interest
TipRanks · 11/30/2025 23:27
Cynata Therapeutics Announces Change in Director’s Securities Interests
TipRanks · 11/30/2025 23:18
More
Webull provides a variety of real-time CYYNF stock news. You can receive the latest news about Cynata Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About CYYNF
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.